Compare MobilEye Global Inc (MBLY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Mesoblast Limited — how do they compare? MobilEye Global Inc trades at $7.11 (market cap $6.00B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: MobilEye Global Inc is far larger — about 3.4× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 7,007,849). Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Mesoblast Limited for 14 Days on average.
| MBLY | MESO | |
|---|---|---|
Market Cap | $6.00B | $1.75B |
Volume | 7,007,849 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $20.96 |
52-Week Low | $6.56 | $13.19 |
Typical Hold Time | 15 Days | 14 Days |
Enterprise Value | $4.56B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $7.15, down 4.28% today, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported revenue growth to $1.89B in 2025 but posted a significant net loss of -$392M, with profitability metrics remaining negative. Recent news highlights ADAS business momentum and strategic investments in autonomous mobility, while analyst consensus remains positive with a $10.83 price target.
The stock presents a high-risk opportunity with strong analyst support but persistent profitability challenges. Upside potential exists from autonomous driving adoption and new program ramps, offset by execution risks and negative cash flow projections for 2026. Current valuation below book value offers margin of safety for long-term investors willing to withstand volatility.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
